• Decitabine: DNA Methyltransferase Inhibitor for Cancer Ep...

  2026-02-15

  Decitabine (5-Aza-2'-deoxycytidine) is an advanced DNA methyltransferase inhibitor that empowers researchers to reactivate silenced tumor suppressor genes and dissect cancer epigenetics in both hematopoietic malignancies and solid tumors. With robust experimental workflows and proven translational value, Decitabine from APExBIO stands out for its reliability, solubility, and validated use in apoptosis induction and DNA hypomethylation studies.

• Belinostat (PXD101): Advanced Insights into Pan-HDAC Inhi...

  2026-02-14

  Explore the latest scientific advances in pan-HDAC inhibition with Belinostat (PXD101), a potent hydroxamate-type histone deacetylase inhibitor. This article delivers a deep dive into epigenetic cancer therapy, innovative in vitro evaluation strategies, and new directions for bladder and prostate cancer research.

• I-BET-762: Selective BET Bromodomain Inhibitor for Epigen...

  2026-02-13

  I-BET-762 is a potent, selective BET inhibitor targeting epigenetic regulation and inflammation. Its high affinity for the BET acetyl-lysine binding pocket enables robust modulation of transcriptional activity and ferroptosis pathways. This article compiles atomic, verifiable facts with direct citation to support its application in preclinical models.

• AZ505, a Potent and Selective SMYD2 Inhibitor: Scenario-D...

  2026-02-13

  Discover how AZ505, a potent and selective SMYD2 inhibitor (SKU B1255), addresses reproducibility and specificity challenges in cell-based assays and epigenetic research. This article presents scenario-driven guidance for bench scientists, grounded in recent literature and practical laboratory experience, to optimize experimental outcomes and streamline SMYD2 inhibition workflows.

• Panobinostat (LBH589): Unraveling HDAC Inhibition and Str...

  2026-02-12

  Explore the unique mechanisms of Panobinostat (LBH589), a broad-spectrum HDAC inhibitor, in apoptosis induction and overcoming drug resistance. This article reveals novel insights into proteotoxic stress, epigenetic regulation, and advanced applications in cancer research.

• NADH (Reduced Nicotinamide Adenine Dinucleotide, CAS No. ...

  2026-02-12

  NADH is a pivotal cellular energy metabolism coenzyme and a sensitive biomarker of metabolic state. Its redox dynamics underpin mitochondrial electron transport chain research and disease modeling, including diabetic nephropathy and cancer metabolism studies. APExBIO offers a rigorously characterized NADH product (SKU: C8749) for research applications requiring high precision and reproducibility.

• Triacetin (SKU BA1710): Scenario-Driven Solutions for Rel...

  2026-02-11

  This article delivers a scenario-based, evidence-backed guide for biomedical researchers and lab technicians seeking to optimize cell viability, proliferation, and cytotoxicity assays using Triacetin (SKU BA1710). By addressing real laboratory challenges, we demonstrate how Triacetin’s chemical stability, mechanistic versatility, and proven safety profile—supported by APExBIO—offer practical workflow advantages and reproducible results.

• AZ505 and SMYD2 Inhibition: Innovations in Epigenetic and...

  2026-02-11

  Explore how AZ505, a potent and selective SMYD2 inhibitor, is pioneering advanced applications in epigenetic regulation, cancer biology, and kidney fibrosis research. This article provides a deep dive into substrate-competitive SMYD2 inhibition and uncovers novel therapeutic insights beyond standard models.

• M344 (SKU A4105): Reliable HDAC Inhibition for Cell-Based...

  2026-02-10

  This article provides scenario-driven, evidence-based guidance on leveraging M344 (SKU A4105)—a potent, cell-permeable HDAC inhibitor—for reproducible cell viability, proliferation, and apoptosis assays in cancer and HIV-1 research. Drawing on data-backed workflow solutions and critical vendor comparisons, it demonstrates why M344 is a trusted tool for biomedical researchers seeking sensitive, validated, and cost-effective epigenetic modulation.

• BRD4770: Reliable G9a Inhibition for Epigenetic Cancer Re...

  2026-02-10

  This article addresses real-world challenges in epigenetic and cell-based assays, demonstrating how BRD4770 (SKU B4837) serves as a reproducible, data-backed solution for histone methyltransferase inhibition. By guiding researchers through scenario-driven Q&A, we highlight the scientific rigor, quality control, and workflow benefits of BRD4770 in cancer biology and cellular senescence studies.

• BRD4770: Advanced Insights into G9a Inhibition and Epigen...

  2026-02-09

  Explore the multifaceted role of BRD4770, a potent G9a histone methyltransferase inhibitor, in epigenetic modulation for cancer research. This article offers novel, in-depth analysis of BRD4770's mechanisms, experimental nuances, and emerging applications beyond current literature.

• DOT1L Inhibition at the Frontier of Translational Oncolog...

  2026-02-09

  This thought-leadership article explores the transformative role of potent and selective DOT1L inhibitors—specifically EPZ-5676—in the landscape of translational cancer research. Blending mechanistic insight with actionable strategies, it covers the molecular rationale for targeting H3K79 methylation, experimental breakthroughs in MLL-rearranged leukemia and multiple myeloma, and the evolving competitive landscape. Strategic guidance for researchers is paired with a visionary outlook on integrating epigenetic therapies in immuno-oncology, all anchored by evidence from recent landmark studies.

• AZ505: A Potent and Selective SMYD2 Inhibitor for Advance...

  2026-02-08

  AZ505, a potent and selective SMYD2 inhibitor, transforms epigenetic and cancer biology research by delivering substrate-competitive inhibition with exceptional selectivity and reproducibility. This article details optimized workflows, practical troubleshooting, and real-world applications for leveraging AZ505 in the study of histone methylation and disease models, empowering researchers to achieve robust, actionable insights.

• BRD4770: G9a Histone Methyltransferase Inhibitor for Adva...

  2026-02-07

  BRD4770 offers researchers a powerful, selective tool for targeting epigenetic vulnerabilities in cancer. By disrupting the c-MYC/G9a/FTH1 axis and inducing cellular senescence, BRD4770 enables robust experimental workflows in both breast and pancreatic cancer models—unlocking new strategies for dissecting tumorigenesis and therapeutic resistance.

• DOT1L Inhibition as a Precision Lever in Epigenetic Cance...

  2026-02-06

  This in-depth thought-leadership article explores the transformative potential of potent and selective DOT1L inhibitor EPZ-5676 in the context of MLL-rearranged leukemia and broader cancer epigenetics. Framed for translational researchers, it unpacks the mechanistic basis of H3K79 methylation inhibition, presents new perspectives on experimental design and workflow optimization, and examines the evolving competitive landscape, all while integrating emerging findings on epigenetic regulation from related domains. By leveraging insights from recent literature, including the interplay of signaling pathways and histone-modifying enzymes, the article contextualizes the unique value proposition of EPZ-5676 from APExBIO and delivers a strategic outlook on future translational directions.

8726 records 30/582 page Previous Next First page 上5页 2627282930 下5页 Last page